X0306 4 2022-02-01 0 0001466301 Clovis Oncology, Inc. CLVS 0001834833 Harding Thomas C. C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 0 1 0 0 See Remarks Common Stock 2022-02-01 4 M 0 1563 A 6958 D Common Stock 2022-02-02 4 S 0 943 1.9397 D 6015 D Common Stock 2022-02-01 4 M 0 1813 A 7828 D Common Stock 2022-02-02 4 S 0 1094 1.9396 D 6734 D Common Stock 2022-02-01 4 M 0 182 A 1733 I By wife Common Stock 2022-02-02 4 S 0 81 1.9396 D 1652 I By wife Restricted Stock Units 2022-02-01 4 M 0 1563 0.00 D Common Stock 1563 6250 D Restricted Stock Units 2022-02-01 4 M 0 1813 0.00 D Common Stock 1813 14500 D Restricted Stock Units 2022-02-01 4 M 0 182 0.00 D Common Stock 182 1450 I By wife Each Restricted Stock Unit represents the right to receive one share of Common Stock. Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $1.89 to $1.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $1.89 to $1.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. On February 1, 2019, the reporting person was granted 25,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. On January 31, 2020, the reporting person was granted 29,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. On January 31, 2020, the reporting person's wife was granted 2,900 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Senior Vice President and Chief Scientific Officer /s/ Thomas Harding 2022-02-02